

ASX ANNOUNCEMENT

1 FEBRUARY 2024



LGP receives \$5 million *R&D rebate*



- Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") is pleased to announce that it has now received its \$5.0 million research and development rebate "**R&D rebate**")
- The Company had previously factored the rebate with Radium Capital leaving a balance of \$2.8 million. The rebate is in addition to the net \$0.36 million R&D rebate received by LGP subsidiary Reset Mind Sciences in the December quarter
- The R&D rebate is the largest R&D rebate amount LGP has claimed to date and reflects the significant R&D expenditure LGP has invested in its multi-faceted R&D program in FY2023, including:
 - developing one of the largest genetic ranges in the Australian and EU markets
 - sponsoring the highly successful QUEST Initiative which was the largest Quality of Life Study globally demonstrating clinically meaningful impacts in a range of indications
 - continuing as leading supplier to the French Pilot program which has directly resulted in the opening of the French market
 - contributing to various peer-reviewed journal articles for the benefit of prescribers and providing in-kind product contributions to multiple University-led studies around Australia to help further both LGP and the Australian industry

ENDS

BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Alistair Warren".

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Paul Long
Chief Executive Officer
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomass per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp